The Importance of PSA Testing in Early Prostate Cancer Screening
Key Indicators for Early Detection
Prostate Specific Antigen (PSA) is an important serum biomarker currently widely used in clinical practice to assess prostate cancer risk, assist in early screening, and monitor treatment effectiveness.
Convenience Advantages of Rapid Testing
Compared to traditional tests that need to be sent to a central laboratory, PSA rapid tests can be performed quickly in non-laboratory settings such as clinics, physical examination centers, and even community service stations, greatly improving the accessibility and efficiency of screening.
Continuously Growing Market Demand
With the increasing global aging trend and the increasing attention of men to prostate health, the market demand for prostate cancer screening is showing a steady growth trend, providing distributors with continuous business opportunities.
reOpenTest PSA Rapid Test: Accurate, Convenient, Reliable
Accurate and Reliable Results
Uses high-quality antibodies and optimized testing systems to ensure high sensitivity and specificity. The test results have good correlation with mainstream laboratory testing methods, providing a reliable basis for initial clinical screening.
Easy to Operate, No Special Equipment Required
Simple sample processing procedures (supports whole blood, serum, and plasma samples) and clear testing steps, no large or special instruments and equipment are required, making it easy to promote and use in various medical service scenarios.
Get Test Results Quickly
Test results can usually be obtained within 10-15 minutes, which is convenient for doctors to quickly assess risks and make subsequent diagnosis and treatment arrangements, improving the patient's experience.
Reasonable Detection Range
The product's detection range covers clinically commonly used PSA screening thresholds (such as 4 ng/mL and other key cut-off values), which can effectively meet the needs of initial screening and risk stratification.
Overview of Key Performance Indicators
reOpenTest PSA rapid test kits have undergone rigorous performance evaluation and demonstrate excellent reliability.
- Diagnostic Sensitivity ≥98% (relative to CLIA)
- Diagnostic Specificity ≥98% (relative to CLIA)
- Detection Range 1-50 ng/mL
*Please refer to the product instructions or contact us for detailed performance data and clinical evaluation reports.
Market Opportunities for Promoting reOpenTest PSA Testing
Seize the Prostate Cancer Screening Market, Choose reOpenTest PSA Testing
reOpenTest PSA rapid test kits are an ideal choice for you to serve relevant clinical departments, physical examination institutions, and expand your men's health testing business line. Its convenience, reliability and cost-effectiveness will bring you significant market advantages. Contact us now for product details, quotes and partnership plans.